Quick Answer
Esperion Therapeutics, Inc. reported Net Income Loss of -$22.68 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +56.2% in Net Income Loss from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: -$13.12 million | Q1 2016: -$14.59 million | Q2 2016: -$14.04 million | Q3 2016: -$17.40 million | Q4 2016: -$28.96 million | Q1 2017: -$40.54 million | Q2 2017: -$43.34 million | Q3 2017: -$45.22 million | Q4 2017: -$37.89 million | Q1 2018: -$46.13 million | Q2 2018: -$45.73 million | Q3 2018: -$49.91 million | Q4 2018: -$60.04 million | Q1 2019: $87.38 million | Q2 2019: -$54.22 million | Q3 2019: -$68.38 million | Q4 2019: -$61.95 million | Q1 2020: -$78.25 million | Q2 2020: $124.61 million | Q3 2020: -$85.44 million | Q4 2020: -$104.48 million | Q1 2021: -$90.94 million | Q2 2021: -$43.67 million | Q3 2021: -$69.39 million | Q1 2022: -$56.73 million | Q2 2022: -$66.32 million | Q3 2022: -$55.12 million | Q1 2023: -$61.72 million | Q2 2023: -$49.94 million | Q3 2023: -$41.25 million | Q1 2024: $61.02 million | Q2 2024: -$61.93 million | Q3 2024: -$29.52 million | Q1 2025: -$40.46 million | Q2 2025: -$12.73 million | Q3 2025: -$31.33 million.
- Over the full 15 years of available data (2011 to 2025), Esperion Therapeutics, Inc.'s Net Income Loss has declined by 109.7%.
- Historical annual values: Fiscal year 2025: -$22.68 million | Fiscal year 2024: -$51.75 million | Fiscal year 2023: -$209.25 million | Fiscal year 2022: -$233.66 million | Fiscal year 2021: -$269.11 million | Fiscal year 2020: -$143.55 million | Fiscal year 2019: -$97.17 million | Fiscal year 2018: -$201.81 million | Fiscal year 2017: -$166.99 million | Fiscal year 2016: -$74.98 million | Fiscal year 2015: -$49.78 million | Fiscal year 2014: -$36.38 million | Fiscal year 2013: -$26.09 million | Fiscal year 2012: -$11.74 million | Fiscal year 2011: -$10.82 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: